We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current BPMC market cap is 6.53B. The company's latest EPS is USD -8.2797 and P/E is -12.88.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 63.29M | 57.57M | 56.57M | 71.96M | 96.12M |
| Operating Income | -124.21M | -129.28M | -128.98M | -105.11M | -78.82M |
| Net Income | -129.56M | -132.79M | -133.71M | -110.92M | 89.14M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 66.51M | 793.74M | 180.08M | 204.04M | 249.38M |
| Operating Income | -361.33M | 308.71M | -641.98M | -537.52M | -486.28M |
| Net Income | -347.69M | 313.88M | -644.09M | -557.52M | -506.98M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 1.22B | 1.11B | 1.11B | 1.05B | 1.04B |
| Total Liabilities | 806.07M | 795.32M | 902.69M | 918.64M | 727.79M |
| Total Equity | 414.3M | 311.13M | 202.61M | 130.61M | 310.69M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 707.69M | 1.72B | 1.25B | 1.35B | 1.05B |
| Total Liabilities | 243.34M | 248.31M | 281.49M | 835.23M | 918.64M |
| Total Equity | 464.36M | 1.47B | 970.74M | 514.68M | 130.61M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -122.96M | -253.44M | -357.92M | -436.85M | -101.51M |
| Investing | 172.79M | 204.86M | 195.27M | 274.04M | 77.13M |
| Financing | N/A | 5.3M | 103.7M | 119.23M | 66.96M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -278.02M | 387.04M | -298.65M | -502.28M | -436.85M |
| Investing | -16.47M | -434.25M | -225.86M | -149.54M | 274.04M |
| Financing | 340.64M | 617.76M | 50.72M | 561.81M | 119.23M |
| Market Cap | 6.53B |
| Price to Earnings Ratio | -12.88 |
| Price to Sales Ratio | 26.18 |
| Price to Cash Ratio | 91.6 |
| Price to Book Ratio | 50 |
| Dividend Yield | - |
| Shares Outstanding | 61.23M |
| Average Volume (1 week) | 508.47k |
| Average Volume (1 Month) | 732.03k |
| 52 Week Change | 96.64% |
| 52 Week High | 111.02 |
| 52 Week Low | 43.89 |
| Spread (Intraday) | 16.99 (14.16%) |
| Company Name | Blueprint Medicines Corporation |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.blueprintmedicines.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
